Efficacy of a complementaryantiinflammatory treatment with erespal in chronic obstructive and non-obstructive bronchitis


如何引用文章

全文:

详细

Aim. To compare efficacy ofatrovent alone and in combination with erespal in patients with chronic
bronchitis (CB) and chronic obstructive pulmonary disease (COPD).
Material and methods. Of 80 participants of the trial (51 male and 29 female - 63.75 and 36.25%,
respectively) who had CB or COPD, 39 patients (28 with CB and 11 with COPD) received 6-month
combined treatment with erespal (160 mg/day) and atrovent (160 meg/day) and 41 patients (32 with
CB and 9 with COPD) received atrovent monotherapy in the same dosage.
Results. Combined therapy produced positive changes in dyspnea, sputum characteristics and its discharge, cough, monotherapy improved sputum discharge and relieved cough; pulmonary ventilation
improved in both groups especially in those on monotherapy. CB patients showed low cytosis, percentage and absolute count of neutrophils, absolute count of lymphocytes and eosinophils in induced sputum. In С В patients percentage of lymphocytes reduced while count of macrophages went up. Combined treatment including erespal also promoted a significant fall of serum and sputum TNFa and
IL-8 reduction in the sputum.
Conclusion. Erespal+atrovent treatment proved more effective than atrovent alone. It is recommended
for both CB and COPD patients without marked disorders of external respiration function.

参考

  1. Edvard Y., Kato G., Bodinier M. С, Chapelain В. Fenspiride et inflammation en pharmacology experimentale. Eur. Respir. Rev. 1991; 1: 33-40.
  2. Pipy В., Pinelli E., Forgue M. F. et al. Fenspiride inhibits arachidonic acid metabolite production and citolic Ca2+ increase by inflammatory macrophages. Eur. Respir. J. 1992; 5: 237.
  3. Carre Ph., Pipy В., Pinelli E. et al. In vitro effects of fenspiride on the production of free oxygen radicals, prostaglandins and leukotrienes by guinea-pig alveolar macrophages. Eur. Respir. Rev. 1991; 1: 79-85.
  4. Безлепко А. В. Опыт длительного применения фенспирида (эреспала) при лечении больных хроническим обструктивным бронхитом. Пульмонология 2002; 3: 76-82.
  5. Волкова Л. И., Букреева Е. Б., Боярко В. В., Полыца Н. Г Опыт применения фенспирида (эреспала) при обострении хронического бронхита. Клин, фармакол. и тер. 2000; 5 (9): 65-68.
  6. Куницына Ю. Л., Шмелев Е. И. Противовоспалительная терапия больных хронической обструктивной болезнью легких. Пульмонология 2003; 2: 111 - 116.
  7. Овчаренко С. И. Противовоспалительная терапия хронического бронхита. Рус. мед. журн. 2001; 9 (5): 2-24.
  8. Akoun G., Arnaud F., Blanchon F. et al. Effect du fenspiride sur la fonction respiratoire et gazometrie de patients presentant une bronchopathie chronique obstructive stable. Eur. Respir. Rev. 1991; 1: 51-56.
  9. Oliveri D., Del Donno M. Etude de faction du fenspiridi (pneumorel 80 mg) sur la clairance mucociliare chez le bronchitique chronique. J. Intern. Med. 1987; 96: 395-398.
  10. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLB/WHO workshop report. 2001.
  11. Fahy J. V., Liu J., Wong H. et al. Cellular and biochemical analysis of induced sputum: reproducibility and validity of cell and fluid-phase measurements. Am. Rev. Respir. Dis. 1993; 147: 1126-1131.
  12. Lensmar C, Elmberger G., Sandgren P. et al. Leukocyte counts and macrophage phenotypes in induced sputum and bronchoalveolar lavage fluid from normal subjects. Eur. Respir. J. 1998; 12: 595-600.
  13. Rutgers S. R., Timens W., Kaufman H. F. Comparison of induced sputum with bronchial wash, bronchoalveolar lavage and bronchial biopsies in COPD. Eur. Respir. J. 2000; 15: 109- 115.
  14. Комлев А. Д., Калинина Н. М., Сысоев К. А. и др. Цитокиновый профиль у больных хронической обструктивной болезнью легких. Мед. иммунол. 2002; 4 (1): 87-92.
  15. Bhowmik A., Seemungal Т., Sapsford R. J. et al. Cytokines in induced sputum during exacerbations of chronic obstructive pulmonary disease. Thorax 2000; 55: 114-120.
  16. Keatings V. M., Collins P. D., Scott D. M., Barnes P. G. Differences in interleukin-8 and tumor necrosis factor in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am. J. Respir. Crit. Care Med. 1996; 153: 530-534.
  17. Richman-Eisenstadt J. B. Y, Jorens P. G., Hebert С A. et al. Interleukin-8: an important chemoattractant sputum of patients with chronic inflammatory airway diseases. Am. J. Physiol. 1993; 264: L413-L418.
  18. Кетлинский С. А., Калинина Н. М. Цитокины мононуклеарных фагоцитов в регуляции воспаления и иммунитета. Иммунология 1995; 3: 15.
  19. Черешнев В. А., Гусев Е. Ю. Иммунология воспаления: роль цитокинов. Мед. иммунол. 2001; 3 (3): 361-368.
  20. Linden М., Rasmussen J. В., Pitulainen E. et al. Airway inflammation in smokers with nonobstructive and obstructive chronic bronchitis. Am. Rev. Respir. Dis. 1993; 148: 1226-1232.
  21. Culpitt S. V., de Matos C, Russell R. E. et al. Effect of theophylline on induced sputum inflammatory induces and neutrophil chemotaxis in chronic obstructive pulmonary disease.Am. J. Respir. Crit. Care Med. 2002; 165: 1371-1376.
  22. Stockleu R. A., Bauley D. L. Validation of assayes for inflammatory mediators in sputum. Eur. Respir. J. 2000; 15: 779- 781. Y
  23. amamoto C, Yoneda Т., Yoshikawa M. et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest 1997; 112: 505-510.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Consilium Medicum, 2004

Creative Commons License
此作品已接受知识共享署名-非商业性使用-相同方式共享 4.0国际许可协议的许可。
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


##common.cookie##